Clinical Trial: A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease

U.S., July 17 -- ClinicalTrials.gov registry received information related to the study (NCT07068165) titled 'A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease' on July 07.

Brief Summary: For patients with active proliferative IgG4-RD, we plan to conduct a 52-week prospective randomized controlled trial to compare the efficacy and safety of 5mg lenalidomide plus prednisone, 10mg lenalidomide plus prednisone, and prednisone alone, so as to find new treatment measures for patients with proliferative IgG4-RD.

Study Start Date: July 07

Study Type: INTERVENTIONAL

Condition: IgG4 Related Disease

Intervention: DRUG: 5mg lenalidomide

Lenalidomide 5mg/d combined with predn...